Total Funding
23
Total FundingSeed raised
Growth Score
pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3312100
Much Better & Less Expensive Drugs
Larry J. Smith: President
About the Company
Netia will license the use of its single strand RNAi drug development platform to pharmaceutical companies; 6 patent filings undergird the technology.
Netia's platform generates better drugs that are much less expensive. The cost to take a conventional drug to market averages $2.6B while a comparable drug based on Netia's platform
costs less than half as much, and reduces the amount of time required to get to market by 3 years. Further, drugs based on the Netia platform can penetrate hundreds of therapeutic targets that are untouchable by conventional drugs.
